J Korean Med Sci.  2012 Nov;27(11):1411-1417. 10.3346/jkms.2012.27.11.1411.

Analgesic Effects of Dexmedetomidine in Vincristine-Evoked Painful Neuropathic Rats

Affiliations
  • 1Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea. demoon@catholic.ac.kr

Abstract

Dexmedetomidine, which is a selective alpha2-adrenoceptor agonist, was recently introduced into clinical practice for its analgesic properties. The purpose of this study was to evaluate the effects of dexmedetomidine in a vincristine-evoked neuropathic rat models. Sprague-Dawley rats were injected intraperitoneally with vincristine or saline (0.1 mg/kg/day) using a 5-day-on, 2-day-off schedule for 2 weeks. Saline and dexmedetomidine (12.5, 25, 50, and 100 microg/kg) were injected to rats developed allodynia 14 days after vincristine injection, respectively. We evaluated allodynia at before, 15, 30, 60, 90, 120, 180, and 240 min, and 24 hr after intraperitoneal drug (normal saline or dexmedetomidine) injection. Saline treatment did not show any differences for all the allodynia. Maximal paw withdrawal thresholds to mechanical stimuli were 3.0 +/- 0.4, 9.1 +/- 1.9, 13.0 +/- 3.6, 16.6 +/- 2.4, and 24.4 +/- 1.6 g at saline, 12.5, 25, 50, and 100 microg/kg dexmedetomidine injection, respectively. Minimal withdrawal frequency to cold stimuli were 73.3 +/- 4.2, 57.1 +/- 6.8, 34.3 +/- 5.7, 20.0 +/- 6.2, and 14.3 +/- 9.5 g at saline, 12.5, 25, 50, and 100 microg/kg dexmedetomidine injection, respectively. Dexmedetomidine shows a dose-dependent antiallodynic effect on mechanical and cold stimuli in vincristine-evoked neuropathic rat models (P < 0.05).

Keyword

Dexmedetomidine; Neuropathy; Pain; Vincristine

MeSH Terms

Analgesics/*therapeutic use
Animals
Behavior, Animal/drug effects
Dexmedetomidine/*therapeutic use
Disease Models, Animal
Hyperalgesia/chemically induced/*drug therapy
Injections, Intraperitoneal
Male
Pain Threshold
Rats
Rats, Sprague-Dawley
Vincristine/toxicity
Analgesics
Dexmedetomidine
Vincristine

Figure

  • Fig. 1 Changes of withdrawal responses during vincristine treatment. (A) Mechanical allodynia. (B) Cold allodynia. (C) Heat hyperalgesia. Results are presented as mean ± standard error of mean (n = 11 in vincristine group, n = 5 in saline group) (*P < 0.01 vs saline; †P < 0.001 vs saline).

  • Fig. 2 Dexmedetomidine affects mechanical allodynia of vincristine treated rats. (A) The withdrawal threshold to mechanical stimuli in the vincristine-induced neuropathic rats. The withdrawal threshold was observed before (Pre) and after injection of normal saline (NS), dexmedetomidine 12.5 µg/kg (DEX12.5), dexmedetomidine 25 µg/kg (DEX25), dexmedetomidine 50 µg/kg (DEX50), dexmedetomidine 100 µg/kg (DEX100). Results are presented as mean ± standard error of mean (n = 6 in saline group, n = 7 per each dexmedetomidine group) (*P < 0.05 vs NS; †P < 0.01 vs NS; ‡P < 0.001 vs NS). (B) Dose-response curve of the percentage maximum possible effect (%MPE) on mechanical analgesia in the dexmedetomidine groups. This shows a mechanical analgesia dose-dependently. Each point is represented the mean ± standard error of mean (n = 6 in saline group, n = 7 per each dexmedetomidine group) (*P < 0.05 vs NS; †P < 0.05 vs 12.5 µg/kg; ‡P < 0.05 vs 25 µg/kg; §P < 0.05 vs 50 µg/kg of dexmedetomidine).

  • Fig. 3 Dexmedetomidine reverses cold allodynia of vincristine treated rats. (A) The withdrawal frequency to cold stimuli. The frequency was measured before (Pre) and after injection of normal saline (NS), dexmedetomidine 12.5 µg/kg (DEX12.5), dexmedetomidine 25 µg/kg (DEX25), dexmedetomidine 50 µg/kg (DEX50), dexmedetomidine 100 µg/kg (DEX100). Results are presented as mean ± standard error of mean (n = 6 in saline group, n = 7 per each dexmedetomidine group) (*P < 0.05 vs NS; †P < 0.01 vs NS; ‡P < 0.001 vs NS). (B) Dose-response curve of the percentage maximum possible effect (%MPE) on cold analgesia in the dexmedetomidine groups. This shows a cold analgesia dose-dependently. Each point is represented the mean ± standard error of mean (n = 6 in saline group, n = 7 per each dexmedetomidine group) (*P < 0.05 vs NS; †P < 0.05 vs 12.5 µg/kg; ‡P < 0.05 vs 25 µg/kg of dexmedetomidine).

  • Fig. 4 The rotarod time of dexmedetomidine-injected rats. Rotarod time was observed before (Pre) and after dexmedetomidine or saline injection. Rotarod time was not decreased by injection of normal saline (NS) and 12.5, 25, and 50 µg/kg of dexmedetomidine. Only 100 µg/kg of dexmedetomidine decreased rotarod time at from 30 to 90 min. Results are presented as mean ± standard error of mean (n = 6 in saline group, n = 7 per each dexmedetomidine group) (*P < 0.001 vs NS).


Reference

1. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008. 44:1507–1515.
2. Park BY, Park SH, Kim WM, Yoon MH, Lee HG. Antinociceptive effect of memantine and morphine on vincristine-induced peripheral neuropathy in rats. Korean J Pain. 2010. 23:179–185.
3. Lynch JJ 3rd, Wade CL, Zhong CM, Mikusa JP, Honore P. Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. Pain. 2004. 110:56–63.
4. Gerlach AT, Murphy CV, Dasta JF. An updated focused review of dexmedetomidine in adults. Ann Pharmacother. 2009. 43:2064–2074.
5. Al-Metwalli RR, Mowafi HA, Ismail SA, Siddiqui AK, Al-Ghamdi AM, Shafi MA, El-Saleh AR. Effect of intra-articular dexmedetomidine on postoperative analgesia after arthroscopic knee surgery. Br J Anaesth. 2008. 101:395–399.
6. Cheung CW, Ng KF, Choi WS, Chiu WK, Ying CL, Irwin MG. Evaluation of the analgesic efficacy of local dexmedetomidine application. Clin J Pain. 2011. 27:377–382.
7. Ohashi Y, Ohta N, Hirao O, Uchiyama A, Mashimo T, Fujino Y. Analgesic effect of dexmedetomidine in a patient with herpetic stomatitis after living-donor lung transplantation. J Anesth. 2008. 22:297–299.
8. Onttonen T, Pertovaara A. The mechanical antihyperalgesic effect of intrathecally administered MPV-2426, a novel alpha2-adrenoceptor agonist, in a rat model of postoperative pain. Anesthesiology. 2000. 92:1740–1745.
9. Nazarian A, Christianson CA, Hua XY, Yaksh TL. Dexmedetomidine and ST-91 analgesia in the formalin model is mediated by alpha2A-adrenoceptors: a mechanism of action distinct from morphine. Br J Pharmacol. 2008. 155:1117–1126.
10. Weng HR, Cordella JV, Dougherty PM. Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia. Pain. 2003. 103:131–138.
11. Nozaki-Taguchi N, Chaplan SR, Higuera ES, Ajakwe RC, Yaksh TL. Vincristine-induced allodynia in the rat. Pain. 2001. 93:69–76.
12. Haselman MA. Dexmedetomidine: a useful adjunct to consider in some high-risk situations. AANA J. 2008. 76:335–339.
13. Virtanen R, Savola JM, Saano V, Nyman L. Characterization of the selectivity, specificity and potency of medetomidine as an a2-adrenoceptor agonist. Eur J Pharmacol. 1988. 150:9–14.
14. Unnerstall JR, Kopajtic TA, Kuhar MJ. Distribution of alpha 2 agonist binding sites in the rat and human central nervous system: analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents. Brain Res. 1984. 319:69–101.
15. Brede M, Philipp M, Knaus A, Muthig V, Hein L. Alpha2-adrenergic receptor subtypes - novel functions uncovered in gene-targeted mouse models. Biol Cell. 2004. 96:343–348.
16. Xu M, Wei H, Kontinen VK, Kalso E, Pertovaara A. The dissociation of sedative from spinal antinociceptive effects following administration of a novel alpha-2-adrenoceptor agonist, MPV-2426, in the locus coeruleus in the rat. Acta Anaesthesiol Scand. 2000. 44:648–655.
17. Pertovaara A, Kauppila T, Jyväsjärvi E, Kalso E. Involvement of supraspinal and spinal segmental alpha-2-adrenergic mechanisms in the medetomidine-induced antinociception. Neuroscience. 1991. 44:705–714.
18. Poree LR, Guo TZ, Kingery WS, Maze M. The analgesic potency of dexmedetomidine is enhanced after nerve injury: a possible role for peripheral alpha2-adrenoceptors. Anesth Analg. 1998. 87:941–948.
19. Can M, Gul S, Bektas S, Hanci V, Acikgoz S. Effects of dexmedetomidine or methylprednisolone on inflammatory responses in spinal cord injury. Acta Anaesthesiol Scand. 2009. 53:1068–1072.
20. Tasdogan M, Memis D, Sut N, Yuksel M. Results of a pilot study on the effects of propofol and dexmedetomidine on inflammatory responses and intraabdominal pressure in severe sepsis. J Clin Anesth. 2009. 21:394–400.
21. Muthuraman A, Singh N, Jaggi AS. Protective effect of Acorus calamus L. in rat model of vincristine induced painful neuropathy: an evidence of anti-inflammatory and anti-oxidative activity. Food Chem Toxicol. 2011. 49:2557–2563.
22. Kiguchi N, Maeda T, Kobayashi Y, Kishioka S. Up-regulation of tumor necrosis factor-alpha in spinal cord contributes to vincristine-induced mechanical allodynia in mice. Neurosci Lett. 2008. 445:140–143.
23. Honore P, Donnelly-Roberts D, Namovic MT, Hsieh G, Zhu CZ, Mikusa JP, Hernandez G, Zhong C, Gauvin DM, Chandran P, et al. A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J Pharmacol Exp Ther. 2006. 319:1376–1385.
24. Kiguchi N, Maeda T, Kobayashi Y, Kondo T, Ozaki M, Kishioka S. The critical role of invading peripheral macrophage-derived interleukin-6 in vincristine-induced mechanical allodynia in mice. Eur J Pharmacol. 2008. 592:87–92.
25. Cata JP, Weng HR, Lee BN, Reuben JM, Dougherty PM. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol. 2006. 72:151–169.
26. Shimode N, Fukuoka T, Tanimoto M, Tashiro C, Tokunaga A, Noguchi K. The effects of dexmedetomidine and halothane on Fos expression in the spinal dorsal horn using a rat postoperative pain model. Neurosci Lett. 2003. 343:45–48.
27. Coggeshall RE. Fos, nociception and the dorsal horn. Prog Neurobiol. 2005. 77:299–352.
28. Sullivan AF, Kalso EA, McQuay HJ, Dickenson AH. The antinociceptive actions of dexmedetomidine on dorsal horn neuronal responses in the anaesthetized rat. Eur J Pharmacol. 1992. 215:127–133.
29. Tanner KD, Reichling DB, Levine JD. Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat. J Neurosci. 1998. 18:6480–6491.
30. Xu B, Zhang WS, Yang JL, Xu H, Deng XM, Zhang YQ. Dexmedetomidine blocks thermal hyperalgesia and spinal glial activation in rat model of monoarthritis. Acta Pharmacol Sin. 2010. 31:523–530.
31. Xu B, Zhang WS, Yang JL, Lû N, Deng XM, Xu H, Zhang YQ. Evidence for suppression of spinal glial activation by dexmedetomidine in a rat model of monoarthritis. Clin Exp Pharmacol Physiol. 2010. 37:e158–e166.
32. Sweitzer SM, Pahl JL, DeLeo JA. Propentofylline attenuates vincristine-induced peripheral neuropathy in the rat. Neurosci Lett. 2006. 400:258–261.
33. Chan AK, Cheung CW, Chong YK. Alpha-2 agonists in acute pain management. Expert Opin Pharmacother. 2010. 11:2849–2868.
Full Text Links
  • JKMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr